Dr. Brendon Stiles will explore the controversial topic of “converting” patients who are considered unresectable into surgical candidates.
Presentations will include data from the POLESTAR, SOHO-01, Beamion LUNG-1, FURTHER, and FLOWERS trials.
During a Health & Wellbeing session, Dr. Mark Lewis will offer strategies for navigating such situations.
Dr. Ioannis Vlahos will address issues radiologists encounter in applying TNM staging guidelines in daily practice.
Prof. John Le Quesne will show how AI can be used to subtype mesothelioma into risk categories and prognosis.
Editors-in-Chief Drs. Alex A. Adjei and Emily Stone will talk with members during a Meet-the-Editor session on Monday afternoon.
An expert panel from the US National Cancer Institute’s Early Detection Research Network provided insights into the current state of the art as well as barriers to use.
However, lead author Dr. Matthew Smeltzer said the new data also show clinicians value biomarker testing more in late-stage disease compared to early-stage disease.
During the session, experts will not only review the updates, they will also discuss how they approached the process and the guidelines’ limitations.
Former IASLC CEO Dr. Paul A. Bunn, Jr., says lung cancer is a global challenge and the unique multinational and multi-specialty nature of the IASLC has helped to build a global response.